Nimacimab
CBeyond
Skye Bioscience · Phase 2 · Active, not recruiting · Enrollment 136
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Nimacimab injection | Population n/r | n/r | n/r | n/r | n/r |
| Nimacimab placebo injection | Population n/r | n/r | n/r | n/r | n/r |
| Semaglutide injection + Nimacimab injection 200 mg | Population n/r | 200 mg | n/r | n/r | n/r |
| Semaglutide injection + Nimacimab placebo injection | Population n/r | n/r | n/r | n/r | n/r |
| Open-label 300 mg Nimacimab injection (study extension) | Population n/r | 300 mg | n/r | n/r | n/r |